An analysis of the NOAH – AFNET 6 trial used large language models to extract AF burden from pacemaker data in patients with device-detected atrial fibrillation. This approach enables to evaluate the impact of AF burden on cardiovascular outcome and on the effectiveness and safety of anticoagulation in pacemaker patients. The AF burden in the population was 0.4%, with 20% of patients showing a baseline AF burden of more than 1%. In these patients, there was no effect of AF burden on stroke or other cardiovascular events. Today, the findings were presented by AFNET board member Prof. Ulrich Schotten, Maastricht, as a hotline at the Heart Rhythm congress 2026 in Chicago (1).